04:25 AM EDT, 06/16/2025 (MT Newswires) -- Sanofi ( SNY ) and Regeneron Pharmaceuticals ( REGN ) said Sunday data from a phase 4 study showed that Dupixent delivered better results than Xolair in adults with severe chronic rhinosinusitis with nasal polyps, a chronic inflammatory condition of the nose, and coexisting asthma.

The drugmakers said Dupixent outperformed Xolair on all primary and secondary efficacy endpoints, with improvements observed as early as week four.

The endpoints that were met include a 1.60-point superior reduction in nasal polyp size as well as an 8.0-point superior improvement in ability to identify different smells, the companies said. Dupixent also led to greater reductions in nasal congestion, they said.

The safety results of the trial were generally consistent with the known safety profile of Dupixent in the drug's approved respiratory indications, Sanofi ( SNY ) and Regeneron said.